Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003673 · ClinicalTrials.gov registry record · Phase 2
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
A Phase 2 study of Leukemia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 10
- Study locations
NCT00003673 is a Phase 2 study of Leukemia that has completed, run by Pfizer. The registered enrollment target is 55 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT00003673, a Phase 2 study of Leukemia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
Conditions Studied
Interventions
- DRUG chemotherapy
- DRUG gemtuzumab ozogamicin
Study Locations (10)
New York
- Long Island Jewish Medical Center - New Hyde Park
- New York Presbyterian Hospital - Cornell Campus - New York
- State University of New York Health Sciences Center - Stony Brook - Stony Brook
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- University of Chicago Cancer Research Center - Chicago
Arizona
- Arizona Cancer Center - Tucson
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Massachusetts
- New England Medical Center Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Pennsylvania
- University of Pennsylvania Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 1998-03 |
| Est. Completion | 1999-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003673
The ClinicalTrials.gov registry entry for NCT00003673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which chemotherapy is the first listed.
NCT00003673 reports 10 study locations spanning 7 distinct geographic areas - top geographies include New York, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00003673 about?
NCT00003673 is a clinical study titled "CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3...
What is the current status of trial NCT00003673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 1998-03. Estimated completion is 1999-03.
What conditions does trial NCT00003673 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00003673?
The interventions under investigation include: chemotherapy (DRUG), gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00003673?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003673 being conducted?
This trial has 10 study locations across Arizona, California, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.